StockData
BioCryst Pharmaceuticals Inc logo

BioCryst Pharmaceuticals Inc (BCRX) stock

BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$7.50+0.05 (+0.67%)

Close on Nov 17, 2026Market cap $1.92BP/E –Yield –

BioCryst Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

BioCryst Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $197.76M, up 15.5% year over year. For fiscal 2025 it was $166.13M, down 4.9% from the year before. Over ten years it grew 8.6% a year on average. The highest annual figure on record is $253.30M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$166.13M-4.9%
FY2024Dec 31, 2024$174.64M-19.4%
FY2023Dec 31, 2023$216.57M-14.5%
FY2022Dec 31, 2022$253.30M+21.3%
FY2021Dec 31, 2021$208.81M+69.8%
FY2020Dec 31, 2020$122.96M+14.8%
FY2019Dec 31, 2019$107.07M+26.1%
FY2018Dec 31, 2018$84.89M+26.8%
FY2017Dec 31, 2017$66.96M+9.8%
FY2016Dec 31, 2016$61.01M-16.1%
FY2015Dec 31, 2015$72.76M+40.5%
FY2014Dec 31, 2014$51.80M+23.5%
FY2013Dec 31, 2013$41.94M-14.7%
FY2012Dec 31, 2012$49.16M-14.1%
FY2011Dec 31, 2011$57.25M-31.8%
FY2010Dec 31, 2010$83.90M+13.9%
FY2009Dec 31, 2009$73.66M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$51.97M+19.8%
Q1 FY2026Mar 31, 2026$60.32M+61.8%
Q4 FY2025Dec 31, 2025$40.87M-17.3%
Q3 FY2025Sep 30, 2025$44.60M+8.6%
Q2 FY2025Jun 30, 2025$43.39M+15.3%
Q1 FY2025Mar 31, 2025$37.27M-19.8%
Q4 FY2024Dec 31, 2024$49.44M-29.4%
Q3 FY2024Sep 30, 2024$41.08M-12.4%
Q2 FY2024Jun 30, 2024$37.62M-26.6%
Q1 FY2024Mar 31, 2024$46.49M-3.9%
Q4 FY2023Dec 31, 2023$70.05M-4.3%
Q3 FY2023Sep 30, 2023$46.88M-11.1%
Q2 FY2023Jun 30, 2023$51.25M-17.3%
Q1 FY2023Mar 31, 2023$48.39M-26.0%
Q4 FY2022Dec 31, 2022$73.21M+15.2%
Q3 FY2022Sep 30, 2022$52.74M+5.5%
Q2 FY2022Jun 30, 2022$61.99M+17.2%
Q1 FY2022Mar 31, 2022$65.36M+54.0%
Q4 FY2021Dec 31, 2021$63.53M+79.7%
Q3 FY2021Sep 30, 2021$49.97M+65.2%
Q2 FY2021Jun 30, 2021$52.87M+92.3%
Q1 FY2021Mar 31, 2021$42.44M+42.1%
Q4 FY2020Dec 31, 2020$35.35M+32.0%
Q3 FY2020Sep 30, 2020$30.25M+20.4%
Q2 FY2020Jun 30, 2020$27.50M-0.7%
Q1 FY2020Mar 31, 2020$29.87M+8.6%
Q4 FY2019Dec 31, 2019$26.77M+14.3%
Q3 FY2019Sep 30, 2019$25.12M+14.2%
Q2 FY2019Jun 30, 2019$27.68M+31.8%
Q1 FY2019Mar 31, 2019$27.49M+49.1%
Q4 FY2018Dec 31, 2018$23.43M+38.4%
Q3 FY2018Sep 30, 2018$22.01M+25.7%
Q2 FY2018Jun 30, 2018$21.01M+33.3%
Q1 FY2018Mar 31, 2018$18.44M+10.0%
Q4 FY2017Dec 31, 2017$16.92M+39.2%
Q3 FY2017Sep 30, 2017$17.51M+24.1%
Q2 FY2017Jun 30, 2017$15.76M–
Q1 FY2017Mar 31, 2017$16.77M–
Q4 FY2016Dec 31, 2016$12.16M–
Q3 FY2016Sep 30, 2016$14.11M–

More BioCryst Pharmaceuticals figures

See a number that looks wrong?